Dec 14

Artiva Named a PM360 2023 Innovative Startup

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis. 

Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved, infusion-ready AlloNK cells from a single umbilical cord blood unit.

Read more about this recognition here.

Recent Posts

See All

BiotechTV: Checking in with Artiva CEO Fred Aslan after the Company’s $167 Million IPO

Fred Aslan describes what the funds will enable Artiva to do in the clinic, and why he believes the company’s non-modified NK cell approach is the best platform for using a cell therapy for autoimmune conditions. Watch the interview here.

Pharmaphorum Podcast: Move over CAR-T – the Potential of NK Cells in Cell Therapy

[excerpt] The early successors in cell therapy have mostly been CAR-T therapies, with the T standing for T cells. But T cells aren’t the only option for cell therapy. Promising work is being done with natural killer, or NK cells, a different kind of immune system cell that could work even better in some ways....

Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK. He answers the following questions: Why do NK cell therapies hold promise in treating autoimmune disease? What is the biggest technical/scientific challenge of developing NK-based therapies, and what...